Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interleukin-1 inhibition with anakinra in resistant myeloproliferative neoplasms
2025-523921-17-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Jul 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anakinra in myeloproliferative disorder (MPD), polycythemia vera (PV), thrombocythemia and 1 more, sponsored by Centre Hospitalier Universitaire de Brest. Primary endpoint: Change in serum calprotectin level at 3 months. Planned start Jul 2026; status: authorised.
02
Drugs
anakinra
03
Conditions
myeloproliferative disorder (MPD)polycythemia vera (PV)thrombocythemiaprimary myelofibrosis (PMF)
Beyond the preview
Go deeper on 2025-523921-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523921-17-00.